Blood products

China Resources Boya Bio-pharmaceutical Group, a key player in blood products and medical aesthetics, has issued a stark profit warning for 2025, forecasting net profit attributable to shareholders

China Resources Boya Bio-pharmaceutical, a key player in biopharmaceuticals, has released a stark profit warning for 2025, forecasting net profit attributable to shareholders at RMB105 million to